Hugh Myrick to Narcotic Antagonists
This is a "connection" page, showing publications Hugh Myrick has written about Narcotic Antagonists.
Connection Strength
0.728
-
Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep. 2004 Oct; 6(5):332-8.
Score: 0.211
-
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
Score: 0.126
-
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
Score: 0.092
-
Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
Score: 0.083
-
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
Score: 0.056
-
Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol. 2005 Jul-Aug; 40(4):297-301.
Score: 0.055
-
New developments in the pharmacotherapy of alcohol dependence. Am J Addict. 2001; 10(s1):s3-s15.
Score: 0.041
-
Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes. Alcohol Clin Exp Res. 2015 Jan; 39(1):79-83.
Score: 0.027
-
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
Score: 0.022
-
Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient. Am J Psychiatry. 2007 Jun; 164(6):979.
Score: 0.016